COVI-MSC

BIOLOGICAL6 trials

Sponsors

Sorrento Therapeutics, Inc.

Conditions

ARDSAcute Respiratory Distress SyndromeArdsCovid19

Phase 2

Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress

WithdrawnNCT04728698

Sorrento Therapeutics, Inc.ARDS, Covid19

Start: 2021-03-31End: 2021-09-30Updated: 2021-09-16

Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

TerminatedNCT04903327

Sorrento Therapeutics, Inc.Covid19

Start: 2021-11-16End: 2022-11-23Updated: 2023-01-09

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Sorrento Therapeutics, Inc.Covid19

Start: 2021-11-16End: 2023-03-31Target: 60Updated: 2022-04-11

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 Long Haul Pulmonary Compromise

WithdrawnNCT04909892

Sorrento Therapeutics, Inc.Covid19

Start: 2021-08-31End: 2022-01-31Updated: 2021-09-16

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome

WithdrawnNCT04909879

Sorrento Therapeutics, Inc.Acute Respiratory Distress Syndrome, Ards

Start: 2021-09-30End: 2022-04-30Updated: 2021-09-24

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 Long Haul Pulmonary Compromise

WithdrawnNCT04992247

Sorrento Therapeutics, Inc.Covid19

Start: 2024-02-29End: 2024-09-30Updated: 2024-04-17